This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This is not a full-text translation of the original article. It is a detailed introduction based on the abstract and bibliographic information available through PubMed, organizing the research purpose, confirmable numbers, limits of causal inference, and safety implications. The central phrase in the title is “temporally associated”; it does not mean that ibogaine was established as the cause of death. The paper should be read as a forensic examination of known cases in which death occurred within a period after ingestion and of the surrounding circumstances.
Ibogaine is a plant-derived psychoactive alkaloid. At the time of the paper, it was being used in both medical and nonmedical settings for purposes related to opioid withdrawal and other substance use. The study’s value lies not in assessing benefits, but in describing backgrounds that may have been shared across fatal cases and making missing information visible.
Study design
The authors treated known deaths temporally associated with ibogaine use outside West and Central Africa from 1990 through 2008 as a consecutive case series. According to the abstract, they systematically reviewed available autopsy records, toxicology records, and investigative records. The series included 19 people—15 men and 4 women, aged 24–54 years. Death occurred 1.5–76 hours after ibogaine ingestion.
This design was neither a clinical trial with a control group nor a cohort study following a defined population to calculate incidence. It was a case series without the denominator of all users, information about people who did not die under similar conditions, or standardized exposure amounts. It can therefore examine the characteristics of the collected deaths and possible contributing factors in the records, but not mortality among all ibogaine users or the causal contribution in each individual.
Content
Observed records
Sufficient postmortem information was available for 14 of the 19 cases. In the authors’ review, 12 of those 14 had an advanced pre-existing medical comorbidity—primarily cardiovascular—and/or one or more commonly abused substances that explained or contributed to death. Other apparent risk factors included seizures associated with alcohol or benzodiazepine withdrawal and use of an ethnopharmacologic iboga product without adequate knowledge.
Clinical and postmortem findings did not suggest a characteristic, consistent neurotoxic syndrome. This does not prove an absence of danger to the nervous system. It means only that no single characteristic pattern was identified within the limited fatality records.
The authors’ assessment and the boundary of causation
The comorbidities and co-used substances described as “explanatory or contributing” in 12 cases indicate that pathways to death may have involved multiple factors. Their presence does not exclude a contribution from ibogaine. Conversely, temporal order alone—the fact that death followed ingestion—cannot establish ibogaine as the sole cause. The paper presents a forensic assessment of association that includes the presence of multiple factors.
Results
The principal numbers are 19 known deaths: 15 men and 4 women, aged 24–54 years, with death occurring 1.5–76 hours after ingestion. Among the 14 cases with sufficient postmortem material, advanced comorbidity, primarily cardiovascular, and/or one or more co-used substances was judged to explain or contribute to death in 12. The other five cases lacked sufficient postmortem data, at least as described in the abstract, and could not be assessed with the same precision.
Important observations are that the deaths did not converge on one uniform neurotoxic picture, and that vulnerabilities or co-used substances were present in many assessable cases. The withdrawal seizures and lack of information about products or methods of use noted by the authors also point to circumstances that cannot be explained by a single chemical alone. These are warning signals for risk management, but without a comparison group and exposure denominator, the increase in probability of death attributable to each factor cannot be calculated.
Limitations
First, “all known cases” does not mean that every death worldwide was completely captured. Unreported cases, inaccessible records, and cases in which ibogaine exposure was not recognized may exist. Second, a case series lacks the denominator of all users and cannot estimate mortality or relative risk compared with other interventions. Third, five of the 19 cases lacked sufficient postmortem information, and the completeness of records and scope of testing may not have been identical even among the other 14.
Comorbid illness, co-used substances, withdrawal state, and the form of product ingested also make it difficult to separate single causes from interactions. From the accessible abstract, doses, purity, routes, and monitoring conditions cannot be compared uniformly across all cases. This introduction does not fill those gaps by speculation or reconstruct individual case narratives or language from the paywalled full text.
Safety
This case series clearly records that deaths have been reported after ibogaine ingestion and that cardiovascular comorbidities or co-used substances were involved in many assessable cases. Seizures related to alcohol or benzodiazepine withdrawal and use of plant products whose constituents and dose were not adequately understood were additional cautions raised by the authors. The statement that there was no characteristic neurotoxic syndrome must not be used as a guarantee of overall safety or as a basis for self-administration.
At the same time, this paper alone cannot determine a common level of risk for all users, a safe range for a particular dose, or the cause of an individual death. The safety information here consists of case records with a temporal association to death; it does not provide diagnosis, dosing decisions, or treatment procedures. Clinical assessment of benefits and risks requires other forms of systematic human data.
Source and rights
The original source can be checked through the PubMed record and abstract and the DOI. It was published in Journal of Forensic Sciences in 2012, volume 57, issue 2, pages 398–412.
The publisher is Wiley, and the identifiable version of record does not state a Creative Commons license generally permitting translation or adapted reuse of the full text. This page is an independent summary based on the public abstract and bibliographic facts, not a full-text translation substituting for the original. Readers seeking individual case details, tables, figures, or exact text should consult legitimate access to the source and the publisher’s terms.